A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1

Lithium (Li) is the cornerstone maintenance treatment for bipolar disorders (BD), but response rates are highly variable. To date, no clinical or biological marker is available to reliably define eligibility criteria for a maintenance treatment with Li. We examined whether the prophylactic response...

Descripción completa

Detalles Bibliográficos
Autores principales: Marie-Claire, C., Lejeune, F. X., Mundwiller, E., Ulveling, D., Moszer, I., Bellivier, F., Etain, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376060/
https://www.ncbi.nlm.nih.gov/pubmed/32699220
http://dx.doi.org/10.1038/s41598-020-69073-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376060/
https://www.ncbi.nlm.nih.gov/pubmed/32699220
http://dx.doi.org/10.1038/s41598-020-69073-0

Ejemplares similares